• Something wrong with this record ?

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

M. Rizzo, A. Soares, E. Grande, A. Bamias, RM. Kopp, E. Lenci, T. Buttner, S. Salah, F. Grillone, IT. de Carvalho, JC. Tapia, C. Gucciardino, A. Pinto, A. Mennitto, H. Abahssain, P. Rescigno, Z. Myint, H. Takeshita, GP. Spinelli, L. Popovic, MG....

. 2024 ; 14 (1) : 19802. [pub] 20240827

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24019259

The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy (SBRT) on the outcome of aUC patients receiving pembrolizumab after platinum-based-chemotherapy. Medical records of 837 patients were reviewed from 60 institutions in 20 countries. Two hundred and sixty-two patients (31%) received radiotherapy (cohort A), of whom 193 (23%) received CRT and 69 (8%) received SBRT. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. With a median follow-up of 22.7 months, the median OS was 10.2 months, 6.8 months and 16.0 months in no RT, CRT and SBRT subgroups (p = 0.005), with an 1y-OS rates of 47%, 34% and 61%, respectively (p < 0.001). The 1y-OS rate in the SBRT subgroup were significantly higher for both lower (63%) and upper tract UC (68%), for pure urothelial histology (63%) and variant histologies (58%), and for patients with bone (40%) and lymph-node metastases (61%). Median PFS was 4.8 months, 9.6 months and 5.8 months in the CRT, SBRT and no RT subgroups, respectively (p = 0.060). The 1y-PFS rate was significantly higher (48%) in the SBRT population and was confirmed in all patient subsets. The difference in terms of ORR was in favour of SBRT. Our real-world analysis showed that the use of SBRT/pembrolizumab combination may play a role in a subset of aUC patients to increase disease control and possibly overall survival.

2nd Propaedeutic Department of Internal Medicine Attikon University Hospital National and Kapodistrian University of Athens Athens Greece

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Centre for Cancer Translational and Clinical Research Institute Newcastle University Newcastle Upon Tyne UK

Clinical Oncology Sociedad de Oncología y Hematología del Cesar Valledupar Colombia

Department of Health Sciences Section of Clinical Pharmacology and Oncology University of Florence Florence Italy

Department of Medical Oncology Azienda Ospedaliera Universitaria Maggiore Della Carità Novara Italy

Department of Medical Oncology Institut d'Investigació Biomèdica Sant Pau Hospital de La Santa Creu 1 Sant Pau Barcelona Spain

Department of Medical Oncology King Hussein Cancer Center Amman Jordan

Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan

Department of Urology University Hospital Bonn Bonn Germany

Division of Medical Oncology Markey Cancer Center University of Kentucky Lexington KY 40536 0293 USA

Division of Medical Oncology National Cancer Centre Singapore Singapore Singapore

Division of Oncology Department of Oncology and Hematology University Hospital of Modena Modena Italy

Genitourinary Medical Oncology Department Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Italy

Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy

Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil

Medical Oncology Department University Hospital La Paz Madrid Spain

Medical Oncology IRCCS Azienda Ospedaliero Universitaria Di Bologna Bologna Italy

Medical Oncology Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy

Medical Oncology Unit Azienda Ospedaliero Universitaria Consorziale Policlinico Di Bari Piazza Giulio Cesare 11 70124 Bari Italy

Medical Oncology Unit Hospital Israelita Albert Einstein São Paulo SP Brazil

Medical Oncology Unit Macerata Hospital Macerata Italy

Medical Oncology Unit Ospedale A Murri Fermo Italy

Medical Oncology Unit Presidio Ospedaliero Pugliese Ciaccio Azienda Ospedaliera Universitaria Renato Dulbecco Catanzaro Italy

Medicine and Pharmacy Faculty Medical Oncology Unit National Institute of Oncology Mohamed 5 University Rabat Morocco

Oncology and Hematology Department Hospital Sírio Libanês Brasília Federal District Brazil

Oncology Institute of Vojvodina Faculty of Medicine University Novi Sad Novi Sad Serbia

Oncology Unit Santa Maria Delle Croci Hospital Department Oncology and Haematology AUSL Romagna Ravenna Italy

Radiation Oncology Unit Hospital Israelita Albert Einstein São Paulo SP Brazil

Radiation Oncology Unit Macerata Hospital Macerata Italy

Territorial Oncology Operative Complex Unit Casa Della Salute di Aprilia ASL Latina Latina Italy

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019259
003      
CZ-PrNML
005      
20241024111358.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-024-70182-3 $2 doi
035    __
$a (PubMed)39187558
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rizzo, Mimma $u Medical Oncology Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico Di Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy. rizzo.mimma@gmail.com
245    10
$a Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study / $c M. Rizzo, A. Soares, E. Grande, A. Bamias, RM. Kopp, E. Lenci, T. Buttner, S. Salah, F. Grillone, IT. de Carvalho, JC. Tapia, C. Gucciardino, A. Pinto, A. Mennitto, H. Abahssain, P. Rescigno, Z. Myint, H. Takeshita, GP. Spinelli, L. Popovic, MG. Vitale, O. Fiala, P. Giannatempo, R. Zakopoulou, F. Carrozza, F. Massari, FSM. Monteiro, MP. Pace, M. Giannini, G. Roviello, C. Porta, N. Battelli, R. Kanesvaran, M. Santoni
520    9_
$a The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy (SBRT) on the outcome of aUC patients receiving pembrolizumab after platinum-based-chemotherapy. Medical records of 837 patients were reviewed from 60 institutions in 20 countries. Two hundred and sixty-two patients (31%) received radiotherapy (cohort A), of whom 193 (23%) received CRT and 69 (8%) received SBRT. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. With a median follow-up of 22.7 months, the median OS was 10.2 months, 6.8 months and 16.0 months in no RT, CRT and SBRT subgroups (p = 0.005), with an 1y-OS rates of 47%, 34% and 61%, respectively (p < 0.001). The 1y-OS rate in the SBRT subgroup were significantly higher for both lower (63%) and upper tract UC (68%), for pure urothelial histology (63%) and variant histologies (58%), and for patients with bone (40%) and lymph-node metastases (61%). Median PFS was 4.8 months, 9.6 months and 5.8 months in the CRT, SBRT and no RT subgroups, respectively (p = 0.060). The 1y-PFS rate was significantly higher (48%) in the SBRT population and was confirmed in all patient subsets. The difference in terms of ORR was in favour of SBRT. Our real-world analysis showed that the use of SBRT/pembrolizumab combination may play a role in a subset of aUC patients to increase disease control and possibly overall survival.
650    _2
$a lidé $7 D006801
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $x aplikace a dávkování $7 D061067
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a urologické nádory $x patologie $x mortalita $x terapie $x farmakoterapie $7 D014571
650    _2
$a radiochirurgie $x metody $7 D016634
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a nádory močového měchýře $x terapie $x patologie $x mortalita $x farmakoterapie $7 D001749
650    _2
$a dospělí $7 D000328
650    _2
$a karcinom z přechodných buněk $x terapie $x patologie $x mortalita $x farmakoterapie $7 D002295
650    _2
$a výsledek terapie $7 D016896
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Soares, Andrey $u Medical Oncology Unit, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil
700    1_
$a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
700    1_
$a Bamias, Aristotelis $u Second Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Kopp, Ray Manneh $u Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia
700    1_
$a Lenci, Edoardo $u Medical Oncology Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
700    1_
$a Buttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), Bonn, Germany
700    1_
$a Salah, Samer $u Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
700    1_
$a Grillone, Francesco $u Medical Oncology Unit, Presidio Ospedaliero Pugliese Ciaccio, Azienda Ospedaliera Universitaria "Renato Dulbecco", Catanzaro, Italy
700    1_
$a de Carvalho, Icaro Thiago $u Radiation Oncology Unit, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
700    1_
$a Tapia, Jose Carlos $u Department of Medical Oncology, Institut d'Investigació Biomèdica Sant Pau, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain
700    1_
$a Gucciardino, Calogero $u Medical Oncology Unit, Ospedale A. Murri, Fermo, Italy
700    1_
$a Pinto, Alvaro $u Medical Oncology Department, University Hospital La Paz, Madrid, Spain
700    1_
$a Mennitto, Alessia $u Department of Medical Oncology, Azienda Ospedaliera Universitaria "Maggiore Della Carità", Novara, Italy
700    1_
$a Abahssain, Halima $u Medicine and Pharmacy Faculty, Medical Oncology Unit, National Institute of Oncology, Mohamed V University, Rabat, Morocco
700    1_
$a Rescigno, Pasquale $u Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK
700    1_
$a Myint, Zin $u Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA
700    1_
$a Takeshita, Hideki $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
700    1_
$a Spinelli, Gian Paolo $u Territorial Oncology Operative Complex Unit - Casa Della Salute di Aprilia - ASL Latina, Latina, Italy
700    1_
$a Popovic, Lazar $u Oncology Institute of Vojvodina, Faculty of Medicine, University Novi Sad, Novi Sad, Serbia
700    1_
$a Vitale, Maria Giuseppa $u Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Giannatempo, Patrizia $u Genitourinary Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
700    1_
$a Zakopoulou, Roubini $u Second Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Carrozza, Francesco $u Oncology Unit, Santa Maria Delle Croci Hospital, Department Oncology and Haematology AUSL, Romagna, Ravenna, Italy
700    1_
$a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy
700    1_
$a Monteiro, Fernando Sabino Marques $u Oncology and Hematology Department, Hospital Sírio Libanês, Brasília, Federal District, Brazil
700    1_
$a Pace, Maria Paola $u Radiation Oncology Unit, Macerata Hospital, Macerata, Italy
700    1_
$a Giannini, Massimo $u Radiation Oncology Unit, Macerata Hospital, Macerata, Italy
700    1_
$a Roviello, Giandomenico $u Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
700    1_
$a Porta, Camillo $u Medical Oncology Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico Di Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy $u Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
700    1_
$a Battelli, Nicola $u Medical Oncology Unit, Macerata Hospital, Macerata, Italy
700    1_
$a Kanesvaran, Ravindran $u Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
700    1_
$a Santoni, Matteo $u Medical Oncology Unit, Macerata Hospital, Macerata, Italy
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 19802
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39187558 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111352 $b ABA008
999    __
$a ok $b bmc $g 2201854 $s 1231232
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $d 19802 $e 20240827 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20241015
Back

Find record

Citation metrics

Archiving options